Tuberculosis remains one of the most consequential infectious disease challenges of our era — and a major new systematic analysis now provides the most comprehensive accounting yet of where the world stands, and how far it has to go. For health professionals, policymakers, and anyone tracking global longevity trends, these estimates arrive at a pivotal moment: recent contractions in global health funding have created real uncertainty about whether hard-won gains can be sustained.
Drawing on the Global Burden of Disease 2023 framework, researchers modeled TB incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) across 204 countries and territories spanning 1990 through 2023. The analysis stratified outcomes by HIV co-infection status and drug-resistance profile, including multidrug-resistant TB (MDR-TB). Mortality was quantified using ensemble cause-of-death modeling incorporating vital registration, surveillance, verbal autopsy, and minimally invasive tissue sampling data, while morbidity was estimated simultaneously via DisMod-MR 2.1. Risk factor attributable fractions were calculated for alcohol use, smoking, and elevated fasting plasma glucose — illuminating how lifestyle and metabolic factors interact with TB vulnerability at a population level.
This analysis is paradigm-relevant rather than merely incremental. The WHO End TB Strategy targets a 95% reduction in TB deaths and a 90% drop in incidence between 2015 and 2035 — thresholds this study is uniquely positioned to evaluate with granular regional and national data. The inclusion of MDR-TB stratification is particularly significant: drug-resistant strains represent a compounding threat where conventional treatment fails and second-line regimens carry substantial morbidity burdens. The HIV-TB interaction layer adds another dimension critical to sub-Saharan Africa and parts of Southeast Asia. Key limitations include the inherent constraints of modeled estimates in countries with weak vital registration systems, where uncertainty intervals are widest. Nonetheless, as a systematic review and meta-analysis anchored in the GBD 2023 methodology, this represents the field's gold-standard baseline — essential for calibrating any future response to funding disruptions or emerging drug resistance.